Skip to main content
. 2025 Aug 21;74(31):484–489. doi: 10.15585/mmwr.mm7431a3

FIGURE 2.

This two-part figure includes two bar charts showing the percentage of infants who received nirsevimab, by their month and year of birth (part A) and by their age group (part B). A total of 23.8% of infants born during October–November 2023 received nirsevimab (part A), and the percentage decreased toward the end of the respiratory virus season to 9.2% among infants born in March 2024. Infants born toward the end of the respiratory virus season who received nirsevimab were more likely to receive the antibodies within the first 3 days of life (45.5% of infants born in March) than were those born at the start of the season (6.2% of infants born in October) (part B).

Percentage of infants immunized against respiratory syncytial virus through receipt of nirsevimab,* by month and year of birth (A) and age group (B) — 33 states and District of Columbia,† October 2023–March 2024

* Calculated as the number of infants who received at least 1 dose of nirsevimab during October 1, 2023–March 31, 2024, divided by the number of infants born each month during October 2023–March 2024 to mothers aged 18–49 years.

† Includes Alaska, Arizona, Arkansas, California, Connecticut, Delaware, Florida, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Mexico, New York, Ohio, Oklahoma, Pennsylvania, South Dakota, Tennessee, Utah, Vermont, Washington, West Virginia, Wisconsin, and Wyoming.